Holen Sie sich die Stockscreener-App
3.825
0.39%
-0.015
Zentalis Pharmaceuticals Inc Aktie (ZNTL) Neueste Nachrichten
Zentalis Pharmaceuticals(ZNTL.US) 10% Shareholder Buys US$15.17 Million in Common Stock - Moomoo
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Group Walters Buys 4,335,000 Shares of Stock - MarketBeat
Walters Group acquires $15.17 million in Zentalis Pharmaceuticals stock - Investing.com
Nearly one-fifth of Zentalis (NASDAQ: ZNTL) sits with one investor group - Stock Titan
Zentalis Pharma closes $92.6 million public offering - The Pharma Letter
New Form 4 Open market buy - Moomoo
Zentalis Pharmaceuticals closes $92.6 million stock offering By Investing.com - Investing.com South Africa
Zentalis Pharmaceuticals closes $92.6 million stock offering - Investing.com
Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Zentalis Pharmaceuticals Announces Closing of Underwritten - GlobeNewswire
GSA Capital Partners LLP Buys New Shares in Zentalis Pharmaceuticals, Inc. $ZNTL - MarketBeat
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Zentalis Pharmaceuticals Shares Fall After Pricing $80.5 Million Offering to Fund Clinical Pipeline - marketscreener.com
Latham Represents Zentalis Pharmaceuticals in US$80.5 Million Underwritten Public Offering - lw.com
symbol__ Stock Quote Price and Forecast - CNN
Why is Zentalis Pharmaceuticals stock tumbling today? By Investing.com - Investing.com Canada
Why is Zentalis Pharmaceuticals stock tumbling today? - Investing.com
Zentalis Pharmaceuticals Shares Fall on Public Offering Pricing - Moomoo
Zentalis Pharmaceuticals (ZNTL) Prices $80.5M Public Offering to Fund Clinical Trials - GuruFocus
Zentalis Pharmaceuticals Prices $80.5 Million Offering to Fund Clinical Pipeline - marketscreener.com
Zentalis Pharmaceuticals prices $80.5M stock offering at $3.50 By Investing.com - Investing.com Australia
Zentalis Pharmaceuticals prices $80.5M stock offering at $3.50 - Investing.com
Zentalis Pharmaceuticals Prices $80.5 Million Public Offering of Common Stock - Quiver Quantitative
Zentalis Sets $3.50 Share Price to Fund Clinical Trials - Stock Titan
Zentalis Pharmaceuticals Announces Pricing Of Underwritten Public Offering - TradingView
Barclays PLC (ZNTL) discloses 2.26M-share, 3.17% stake in Zentalis - Stock Titan
Zentalis Pharmaceuticals announces public stock offering By Investing.com - Investing.com Australia
Zentalis Pharmaceuticals announces public stock offering - Investing.com
Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering - TradingView
Zentalis Pharmaceuticals stock falls on public offering news By Investing.com - Investing.com Nigeria
Zentalis Pharmaceuticals stock falls on public offering news - Investing.com
Mizuho Securities Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Maintains Target Price $8 - Moomoo
HC Wainwright Analysts Decrease Earnings Estimates for ZNTL - MarketBeat
Zentalis Pharmaceuticals (ZNTL) Slips to $4.15 Amid Cautious Biotech TradingDemand Zone - dars.gov.et
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Cut to Strong Sell at Wall Street Zen - MarketBeat
Morgan Stanley Maintains Zentalis Pharmaceuticals(ZNTL.US) With Hold Rating, Raises Target Price to $5 - Moomoo
H.C. Wainwright Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Zentalis Highlights Q2 Results and Azenosertib Progress - The Globe and Mail
Wedbush Adjusts Price Target on Zentalis Pharmaceuticals to $5 From $4, Maintains Neutral Rating - Moomoo
Zentalis Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $7.44, Implies 49% Upside - TradingView
Morgan Stanley Adjusts PT on Zentalis Pharmaceuticals to $5 From $4, Maintains Equalweight Rating - marketscreener.com
Renaissance Technologies LLC Lowers Position in Zentalis Pharmaceuticals, Inc. $ZNTL - MarketBeat
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Releases Earnings Results - MarketBeat
ZNTL Advances Clinical Trials for Ovarian Cancer Drug Amid Valua - GuruFocus
Zentalis Pharmaceuticals, Inc. 2Q 2026: Net loss $(42.3M), EPS $(0.59) — 10-Q Summary - TradingView
Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates - The Manila Times
Zentalis Q2 FY26 net loss widens to $42.29 million - Bitget
ZNTL: Clinical and regulatory progress advances, with $174.6M cash runway into late 2027 despite higher losses - TradingView
ZNTL: Q2 2026 net loss widened to $42.3M as R&D spending rose for late-stage azenosertib trials - TradingView
BlackRock, Inc. Expands Stake in Zentalis Pharmaceuticals (ZNTL) with Strategic Share Addition - GuruFocus
ZNTL Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
ZNTL Q1 2026 Earnings: Wider-Than-Expected Loss Underscores Clinical-Stage ProfileAnalyst Consensus Shift - vinanet.vn
Zentalis Pharmaceuticals Inc expected to post a loss of 49 cents a shareEarnings Preview - TradingView
BlackRock (NYSE: BLK) discloses 5.2% ownership in Zentalis Pharmaceuticals (ZNTL) - Stock Titan
Zentalis Pharmaceuticals Market Sentiment - Benzinga España
Zentalis Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ZNTL - TradingView
TradingKey - TradingKey
1.21%
1.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):